Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective?

American Journal of Nephrology

Volumn 46, Issue 2, 2017, Pages 96-107

  Caliskan, Yasar ^a   Torun, Ege Sinan ^a   Tiryaki, Tarik Onur ^a   Oruc, Aysegul ^b   Ozluk, Yasemin ^a   Akgul, Sebahat Usta ^a   Temurhan, Sonay ^a   Oztop, Nida ^a   Kilicaslan, Isin ^a   Sever, Mehmet Sukru ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

C3 glomerulopathy; Complement system; End stage renal disease; Proteinuria

Indexed keywords

ALBUMIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLATE MOFETIL; PREDNISOLONE; ANTIINFLAMMATORY AGENT; C3 PROTEIN, HUMAN; CREATININE; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANEMIA; ARTICLE; BLADDER DISEASE; BLOOD CELL COUNT; CLINICAL OUTCOME; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FIBROSING ALVEOLITIS; GENDER; GLOMERULOPATHY; HEMATURIA; HISTOPATHOLOGY; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NAUSEA; NEPHROTIC SYNDROME; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; SANGER SEQUENCING; THROMBOCYTOPENIA; AGE; BIOPSY; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DISEASE EXACERBATION; FIBROSIS; GLOMERULONEPHRITIS; GLOMERULUS; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; TREATMENT OUTCOME; URINE; YOUNG ADULT;

ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; BIOPSY; COMPLEMENT C3; CREATININE; DISEASE PROGRESSION; FEMALE; FIBROSIS; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; PROTEINURIA; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85023751797     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000479012     Document Type: Article

References (27)

1. Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC: C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6: 494-499.
2. D'Agati VD, Bomback AS: C3 glomerulopathy: what's in a name. Kidney Int 2012; 82: 379-381.
3. Caliskan Y: Complement pathway associated glomerulopathies. EMJ 2016; 1: 30-38.
4. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH, Theis JD, Dogan A, Smith RJ: C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82: 465-473.
5. Barbour S, Gill JS: Advances in the understanding of complement mediated glomerular disease: implications for recurrence in the transplant setting. Am J Transplant 2015; 15: 312-319.
6. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, Teoh CW, Awan A, Waldron M, Cairns T, O'Kelly P, Dorman AM, Pickering MC, Conlon PJ, Cook HT: C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014; 9: 46-53.
7. Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015; 88: 1153-1160.
8. Giaime P, Daniel L, Burtey S: Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy. Clin Nephrol 2015; 83: 57-60.
9. Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB: Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756.
10. Le Quintrec M, Lionet A, Kandel C, Bourdon F, Gnemmi V, Colombat M, Goujon JM, Frémeaux-Bacchi V, Fakhouri F: Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 2015; 65: 484-489.
11. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657.
12. McCaughan JA, O'Rourke DM, Courtney AE: Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 2012; 12: 1046-1051.
13. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT: C3 glomerulopathy: consensus report. Kidney Int 2013; 84: 1079-1089.
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
15. Summary of recommendation statements. Kidney Int Suppl (2011) 2013; 3: 5-14.
16. Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, Somers MJ, Trachtman H, Waldman M; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glo merulonephritis. Kidney Int Suppl 2012; 2: 221-232.
17. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association: Joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR/ ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71: 1771-1782.
18. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2: 139-274.
19. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD: Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 2009; 4: 22-32.
20. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grunfeld JP, Niaudet P, Lesavre P, Frémeaux-Bacchi V: Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012; 82: 454-464.
21. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J: Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 1983; 74: 175-192.
22. Vikse BE, Bostad L, Aasarød K, Lysebo DE, Iversen BM: Prognostic factors in mesangioproliferative glomerulonephritis. Nephrol Dial Transplant 2002; 17: 1603-1613.
23. Bomback AS, Appel GB: Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol 2012; 8: 634-642.
24. Nester CM, Smith RJ: Treatment options for C3 glomerulopathy. Curr Opin Nephrol Hypertens 2013; 22: 231-237.
25. Mario Negri Institute for Pharmacological Research. Alexion Pharmaceuticals. Eculizumab in Primary MPGN (EAGLE). NCT02093533. https: //clinicaltrials. gov/ct2/ show/NCT02093533.
26. Dragon-Durey MA, Frémeaux-Bacchi V, Loirat C, Blouin J, Niaudet P, Deschenes G, Coppo P, Herman Fridman W, Weiss L: Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15: 787-795.
27. Chen Q, Müller D, Rudolph B, Hartmann A, Kuwertz-Bröking E, Wu K, Kirschfink M, Skerka C, Zipfel PF: Combined C3b and Factor B autoantibodies and MPGN type II. N Engl J Med 2011; 365: 2340-2342.